Prospective Study
Copyright ©The Author(s) 2024.
World J Crit Care Med. Sep 9, 2024; 13(3): 96132
Published online Sep 9, 2024. doi: 10.5492/wjccm.v13.i3.96132
Table 2 Vasopressor requirement and complications according to the groups
Parameters
Group
P value
Low T3
Low T3T4
Vasopressors, No/Yes (%)
Norepinephrine0/24 (0.0/100.0)0/23 (0.0/100.0)Constant
Vasopressin9/15 (37.2/62.5)12/11 (54.2/45.8)0.311
Dobutamine14/10 (58.3/41.7)4/19 (17.4/82.6)0.003
Epinephrine18/6 (75.0/25.0)4/19 (17.4/82.6)0.000
Complications, No/Yes (%)
Pneumonia19/5 (79.2/20.8)16/7 (69.6/30.4)0.450
ARDS16/8 (66.7/33.3)15/8 (65.2/34.8)0.916
Renal failure20/4 (83.3/16.7)7/16 (30.4/69.6)0.000
Liver failure18/6 (75.0/25.0)20/3 (87.0/13.0)0.297
MOF19/5 (79.2/20.8)6/17 (26.1/73.9)0.000